Search PubMed⌕ Search

Biomedical subjects

B Hoerni

Publications and source records attributed to B Hoerni.

At least 127 records · Page 7Linked to original sources
PubMed1981

[Chemotherapy associating mitomycin C, thiotepa and vindesine in advanced breast cancers. Study of 100 cases (author's transl)].

One hundred patients suffering from advanced breast cancers and resisting to one (15) or several (85) drugs previously administered have been treated by an association of mitomycin C, thiotepa and vindesine, given every 3 weeks. Toxic effects were frequently observed and it was necessary to stop the treatment in more than 25 p. cent of the patients. Hemorrhagic complications due to thrombopenia (50 p. cent of cases) were severe in few cases and were responsible for the death of 2 patients. An overall objective response has been obtained in 41 cases and a regression in more than 50 p. cent of the lesions with a median duration of 7.5 months has been observed in 15 cases. The most striking effects have been noted in lymph nodes and skin involvement with an appreciable effect on the functional (subjective) and painful syndrome in 60 p. cent of cases. Difficulties in applying this chemotherapy to patients who had already been heavily treated explain a toxicity which would probably be reduced by an earlier application of the treatment. The quality of the results obtained (here) with these patients incite to study the effect of this association primarily to improve the long-term prognosis of localized or already disseminated breast cancers.

Adenocarcinoma↗
PubMed1981

[Combination treatment of localised breast cancers with a high risk of metastatic disease. The results of a prospective controlled study (author's transl)].

74 patients who had adenocarcinoma of the breast that was inoperable at the beginning because of local extension but without inflammation and without diagnosable metastases (T3b, T4, N1, 2 or 3, Mo) were submitted to a therapeutic regime which consisted consecutively of: 1) preliminary chemotherapy, 2) radiotherapy and/or extended radical surgery when there was any residual tumour, and 3) follow-up adjuvant chemotherapy. Two types of combinations of cytostatic drugs were used: adriamycin, vincristin and methotrexate (AVM) for 5-day cycles every 3 weeks, and cyclophosphamide, methotrexate and fluoro-uracil (CMF) in 14-day cycles every 4 weeks. Three to 5 cycles of AVM were used initially, then at first either AVM to a total of 550 mg/m2 adriamycin, or a series of CMF carried on for a year. Complete remission was obtained in 70% of the patients (52 out of 74) at the end of the local-regional treatment. The mean time of remission was 33 months and the mean time of overall survival was 43 months. The best results were obtained in younger women (under 65 years of age) with tumours that were less developed (T3b), and who could take all the adjuvant chemotherapy after they had complete remission. There was no relapse in 37 of the 48 patients in this group (77% of the cases). Overall the treatment was tolerated fairly well and there was no major complication at the time of radiotherapy or surgery. These results are comparable to those from other studies of a similar nature and show a real progress as compared with those that used to be obtained when only local and regional treatments were undertaken. A more thorough follow-up is however necessary since we can hope for improvements to increase the efficacy and tolerance of the treatments, but this form of treatment can here and now be considered as an important factor for improving the survival rate of these very high risk patients.

Aged↗
PubMed1981

The prognostic significance of specific histologic features of carcinoma of the colon and rectum.

The prognostic significance of several histologic features of the primary tumors and regional lymph nodes was analyzed in 82 consecutive patients with carcinoma of the colon and rectum. Three criteria were shown to have a statistically significant favorable impact on prognosis: Dukes' A or B stage, the absence of mucinous components and the presence of lymphoplasmocytic infiltration in or around the tumor. Based upon the number of these criteria present, we were able to separate the patients into three distinct prognostic groups. We suggest that such a grouping is simple and should be considered in the design and analysis of future adjuvant trials done for carcinoma of the colon and rectum.

Adult↗
PubMed1980

Hodgkin's disease, clinical stages I and II. Results of radical irradiation with or without chemotherapy.

From 1965 to 1976, 170 patients with Hodgkin's disease, clinical stages I or II, were treated with radical irradiation. A first group of 42 patients was treated with irradiation alone, a second group of 24 patients received one course of chemotherapy followed by irradiation, and a third group of 104 patients was treated with a sandwich regimen including chemotherapy + irradiation + chemotherapy. Although the treatment were not randomized, the comparison of the results shows a striking improvement in the group submitted to the C + R + C regimen: in this group the plateau of disease-free survival was 90 per cent. This result was obtained after treatment for about 3 months without surgical staging or maintenance chemotherapy. However, this treatment may favor some complications,. mainly the development of a second malignancy; these risks may be decreased by reducing the treatment in patients with good prognosis.

Adult↗
PubMed1980

[Chemotherapy in cervical cancer. Assessment of 267 palliative treatments and current trends (author's transl)].

Over the last 10 years 267 treatments with cervical cancer have been treated with chemotherapy in 4 anticancer centers. The analysis of these results shows: 1) 9 per cent of the treatments were discontinued because of clinical and hematological intolerance reactions; these intolerance reactions were responsible for 1 per cent of the therapeutic deaths; 2) an effect on the functional symptoms in 52 per cent of the patients with multiple drug regimens; 3) an objective global response in 18 per cent of the patients treated with single drug therapy (3 regressions greater than 50% out of 6 cases treated with cis-platinum) and in 22 per cent of the patients treated with various associations. Comparison of these results to recent data in the literature confirms: 1) the hope of improving objective results by developing more rational protocols of association, since, for the moment more active drugs are not available; 2) a much more marked chemotherapeutic action on lesions which have not been previously irradiated (statistically significant differences in response). Chemoresistance in cervical cancers may not be as frequent or as insurmountable as generally believed. The role of chemotherapy may be visualized from: 1) the palliative point of view, for efficacy while reducing toxicity); 2) induction sequence in curative treatment programs for advanced local forms with unfavorable prognosis (logical and attractive orientation of therapeutic studies); 3) the point of view of adjuvant treatment which remains to be defined. Rigorous studies are required to assess whether chemotherapy can give eventual long term improvement in high risk cervical cancers.

Adenocarcinoma↗
PubMed1980

[Non-Hodgkin's malignant lymphomas. Clinico-pathological data and course in 370 patients (author's transl)].

Three hundred and seventy non-Hodgkin's malignant lymphomas were seen at the Fondation Bergoniéé between 1965 and 1978 and classified according to the Kiel classification. Pretherapeutic data and evolution allow to recognize three distinct pathologic groups: 1) a first type of lymphosarcoma, so-called "low grade malignancy", is observed only in adults and old patients; the disease is often disseminated, the evolution is slow and the prognosis favorable; 2) a second type, so-called "lymphoblastosarcoma", is only one observed in young patients, the evolution is fast with frequent leukemic transformation and this group is thus very close to acute lymphoid leukemia; 3) a third type, so-called "immunoblastosarcoma", is observed only in old patients; the evolution is fast but without major spread; for these two latter groups, the prognosis is unfavorable. This highly significant and clearcut distinction may be a help for scheduling treatment according to each group of patients.

Humans↗
PubMed1980

[Combination chemotherapy of anaplastic carcinoma with adriamycin, vincristine, methotrexate and cyclophosphamide (author's transl)].

Taking into account the evolutive features of anaplastic cancers, the authors used four-drug combination chemotherapy with adriamycin, vincristine, methotrexate and cyclophosphamide applied to 55 patients. Treatment was administered in courses of 3 weeks at 15-day intervals and consisted of 3 days of treatment/week, repeated every 15 days. On the whole the treatment was well tolerated; however, the use of adriamycin was restricted because of its cumulative toxicity. Immediate objective responses were observed in 48 patients (87% of the cases) with 32 tumor regressions < 50 per cent (58%), 14 of which were complete remissions. The effects were most distinctive in distant lymph node metastases (78%). In the majority of cases the effects were of brief duration. Whether or not radiotherapy was associated, the overall course of the disease was not significantly influenced. The authors point out that patients responding to this protocol did not achieve the median survival, whereas the median survival was 17 months for an identical period of observation with varied treatments used priorly. The authors conclude that this chemotherapeutic protocol needs to be reinforced and readjusted in order to improve long term results.

Adult↗
PubMed1979

Successful maintenance immunotherapy by BCG of non-Hodgkin's malignant lymphomas: results of a controlled trial.

Forty-eight patients less than 65 years old, suffering non-Hodgkin's malignant lymphomas with one or more criteria of poor prognosis, were priorly placed in complete remission by an association of chemo + radio + chemotherapy. They were then randomized to receive either BCG in weekly scarifications for 3 years or no further treatment. Five patients were excluded (four after pathological reassessment); 43 are thus evaluable. There were 13 relapses out of 23 control patients and three relapses out of 20 treated patients (0.01 less than P less than 0.025). This difference is more distinct for clinical stages I and II (0.01 less than P less than 0.025) than for stages III and IV (not significant). Eight patients died in the control group whereas there was only one death in the treated group (0.025 less than P less than 0.05). These results indicate than BCG is useful in maintaining remission in about 40% of the cases and also in increasing their survival, especially in patients with clinical stages I or II.

Adolescent↗
PubMed1979

Lymphography in angio-immunoblastic lymphadenopathy.

Angio-immunoblastic lymphadenopathy (AIL) produces a characteristic lymphoproliferative syndrome, with characteristic lymphographic appearances. The authors studied the lymphographic manifestations of 18 cases of AIL. In 15 out of 18 cases, enlargement is observed in all the lymph nodes with a lacy or reticular storage pattern and sharp, well delimited margins. This lymphographic appearance reflects the histologic changes; only the peripheral sinuses, which are not involved, can be observed on lymphography.

Adult↗